65,437 trials
Influenza
Primary: Number of Subjects Reporting Fever — 3; 0 participants
Diabetic Nephropathy · Chronic Kidney Disease
Primary: Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine…
Papillomavirus Infections
Primary: Number of Participants Who Seroconvert to HPV 6. — 109; 0 Participants
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir — 385.35; 350.86 ng/mL
Benign Prostatic Hyperplasia
Primary: Number of Men With Treatment-emergent Dizziness — 9; 11 Participants — p=0.403
Dental Plaque
Primary: Triclosan Concentration in Dental Plaque — 0; 1.8 ppm levels of triclosan — p=0.05
Healthy
Primary: Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma) — 509.63; 538.11 ng/mL
Healthy
Primary: Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma) — 458.29; 409.324 ng/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2.60; 2.56 ng/mL
Colorectal Cancer
Primary: Progression-Free Survival (Oxaliplatin) — 10.0; 11.4 Month — p=0.011
Healthy
Primary: Cmax of Buprenorphine. — 4.40; 3.88 ng/mL
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward — -0.3; -0.6; -0.9; -1.0 Percernt
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 8.8694; 9.0150 ng/mL
Serious Fungal Infections
Primary: Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable — 36.83; 26.52; 16.94; 19.71 Percentage of participants
Chemotherapy-Induced Thrombocytopenia · Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Change in Platelet Nadir — 17.1; 11.2; 5.1; -5.2 10^9/L — p=0.9654